Seed · Biotech · Cambridge, United Kingdom · Founded 2017 · 11–50 employees
Mursla Bio is a biotechnology company pioneering Extracellular Vesicle (EV) science to deliver next-generation multi-omics liquid biopsy tests and precision diagnostics. Using its proprietary AI Precision Medicine Platform, the company non-invasively analyzes organ-specific EVs isolated from small blood samples to provide tissue-resolved, high-dimensional molecular insights. Its flagship product in development, EvoLiver™, has received FDA Breakthrough Device Designation and is designed for the early surveillance of liver cancer in high-risk patients. The company also collaborates with global pharmaceutical companies to apply its platform toward biomarker-guided drug development in metabolic liver diseases. Additionally, the company has been invited as the lead industrial partner of the EVEREST European Consortium.
No open roles listed right now.